Safemedwaste, Inc.

08/06/2024

Go Fig, Little Beeings, Sphere, Strata Platforms, RFIDKNOW, and Tabbi were accepted as South Carolina Research Authority Member Companies. Imagine Home Digital, MyUI, MyVoluntier Operations, SafeMedWaste, and Virtual Business 360 received new grant funding.

04/04/2024

NATIONAL PRESCRIPTION DRUG TAKE BACK DAY 2024!

Help protect your loved ones and the environment by properly disposing of unused prescription drugs in the home. You CAN make a difference.

Learn more: https://www.campusdrugprevention.gov/national-prescription-drug-take-back-day?utm_medium=email&utm_source=govdelivery

01/18/2024

DEA Adds Precursor Chemicals Used to Make Illicit Fentanyl to the Special Surveillance List.

This is the first update to the Special Surveillance List since it was published in 1999.

Fentanyl is the greatest threat facing Americans today. It is a threat to our public health, our public safety, and our national security, and it is the cause of the most devastating drug crisis in United States’ history. The U.S. Drug Enforcement Administration (DEA) is committed to using every t...

12/18/2023

The team at Safemedwaste, Inc. wishes everyone a safe and happy holiday season.

11/01/2023

OPERATION BOTTLENECK (October 31, 2023). DEA announces actions against six DEA-registered companies which, together, failed to account for more than a million doses of opioids.

https://www.dea.gov/press-releases/2023/10/31/dea-executes-operation-bottleneck-prevent-diversion-controlled-substances

, ,

Secure .gov websites use HTTPSA lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

10/20/2023

Don't forget to mark your calendar! The DEA drug take back day is just around the corner. Learn more about the event and drop off locations:

The drug overdose epidemic in the United States is a clear and present public health, public safety, and national security threat. DEA’s National Prescription Drug Take Back Day reflects DEA’s commitment to Americans’ safety and health, encouraging the public to remove unneeded medications fro...

10/19/2023

FDA approves new non-opioid, post-operative pain medication.

, ,

The U.S. health regulator has approved Hyloris Pharmaceuticals' drug for post-operative pain, the Belgium-based company said on Wednesday, adding that it expects to launch the non-opioid treatment in the United States by early next year.

10/09/2023

A QUICK OVERVIEW OF THE WASTE REFUND ACT: Required CMS Refunds Effective January 1, 2023.

As part of the infrastructure bill passed in 2021, the Waste Refund Act requires drug companies to reimburse Medicare for certain wasted medications leftover in single-use containers.

Healthcare facilities (hospitals, ASC's, etc.) that do not report their wastage refunds correctly could be at risk of failed audits and being charged with healthcare fraud.

Learn more about the requirements

The-infrastructure-bill-that-passed-on-Nov-15-2021-garnered-much-media-attention-for-its-focus-on-bridges-and-other-long-neglected-systems

08/11/2023

The Biden-Harris Administration Awards More Than $88 Million in Grants that Safeguard Youth Mental Health and Expand Access to Treatment for Substance Use Disorders.

If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn how to get support for mental health, drug or alcohol issues, visit FindSupport.gov. If you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 1-800-662-HELP (4357).

, ,
https://www.samhsa.gov/newsroom/press-announcements/20230811/biden-harris-administration-awards-grants-safeguard-youth-mental-health-expand-access-treatment-substance-use-disorders?utm_source=SAMHSA&utm_campaign=f73417bd91-EMAIL_CAMPAIGN_2023_08_11_02_20&utm_medium=email&utm_term=0_-f73417bd91-%5BLIST_EMAIL_ID%5D

The U.S. Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), has recently awarded more than $88 million in its continuing effort to safeguard the nation’s behavioral health. The grant programs serve a wide array of needs .....

08/02/2023

ALERT: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

ACTION: Temporary amendment; temporary scheduling order.

SUMMARY: The Administrator of the Drug Enforcement Administration is issuing this temporary order to schedule five synthetic benzodiazepine substances: etizolam, flualprazolam, clonazolam, flubromazolam, and diclazepam, in schedule I of the Controlled Substances Act. This action is based on a finding by the Administrator that the placement of these five substances in schedule I is necessary to avoid imminent hazard to the public safety. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specified controlled substances.

DATES: This temporary scheduling order is effective July 26, 2023, until July 26, 2025. If this order is extended or made permanent, DEA will publish a document in the Federal Register.

05/25/2023

Okra Medical's office will be closed on Monday, May 29th in observance of the Memorial Day holiday. Regular office hours will resume on Tuesday, May 30th. On behalf of the entire Okra Medical team, we extend our heartfelt gratitude to all the fallen heroes and their families.